Ignite Creation Date:
2024-05-05 @ 11:40 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00102765
Status:
COMPLETED
Last Update Posted:
2017-01-18
First Post:
2005-02-01
Brief Title:
Study Of Asthma In Patients Of African Descent
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Parallel Group 52-Week Comparison of Asthma Control and Measures of Airway Inflammation in Subjects of African Descent Receiving Fluticasone PropionateSalmeterol 10050mcg DISKUS BID or Fluticasone Propionate 100mcg DISKUS BID Alone
Status:
COMPLETED
Status Verified Date:
2017-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will last up to 62 weeks You will visit the clinic up to 17 times Certain clinic visits will include physical examination medical history review and lung function tests The purpose of this study is to see if one asthma drug fluticasone propionatesalmeterol is better in reducing the number of asthma exacerbations compared with another drug fluticasone propionate alone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None